Skip To Main Content
Dylan Westfall on Muck Rack

Dylan Westfall

As seen in: Nature, Cell Host & Microbe
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Dylan Westfall’s profile

Articles by Dylan Westfall

Prophylactic treatment with broadly neutralizing antibody VRC01 selects for escape mutants after infection in Antibody-Mediated Prevention trials

|
By Carolyn Williamson, Nonhlanhla N. Mkhize, Elena Giorgi, Craig A Magaret, Bronwen E. Lambson, Sinethemba Bhebhe, Haajira Kaldine, Thandeka Moyo-Gwete, Morgane Rolland, Raabya Rossenkhan, Nina Garcia Verified, Chivonne Moodley, Anna Yssel, Yunda Huang, Daniel Reeves, Bryan Mayer, Roger E. Bumgarner, Nicolas Beaume, Dylan Westfall, Michal Juraska, Allan C. deCamp, Hugh Murrell, Hongjun Bai, Wenjie Deng, Alec Pankow, Tanmoy Bhattacharya, Talita York, Nonkululeko Ndabambi, Lennie Chen, Hong Zhao, Ruwayhida Thebus, Paula Cohen, Ben Murrell, Shelly Karuna, John Hural, Nyaradzo Mgodi, Srilatha Edupuganti, Lynn Morris, David C. Montefiori, M. Juliana McElrath, Myron Cohen, Lawrence Corey, Paul T. Edlefsen, Peter Gilbert, Penny Moore, James Mullins, Lyle Curry, Alaine A. Marsden, Asanda Gwashu-Nyangiri
| Nature Verified
Abstract Broadly neutralizing antibodies (bnAbs) show promise in HIV prevention, yet viral escape remains a challenge. In the Antibody-Mediated Prevention (AMP) trials, the CD4 binding site (CD4bs) bnAb VRC01 blocked acquisition by VRC01-sensitive strains. However, its influence on viral evolution post acquisition is not fully understood.
Open in Who Shared Issue with article?

Long-read deep sequencing reveals high rates of multilineage transmission and rapid viral population changes in acute HIV infection

|
By James Mullins, Wenjie Deng, Elena Giorgi, Craig A Magaret, Morgane Rolland, Tanmoy Bhattacharya, Dylan Westfall, Anna Yssel, Roger E. Bumgarner, Ben Murrell, Thumbi Ndung’u, Merlin L. Robb, Raabya Rossenkhan, Paul T. Edlefsen, Krista L Dong, Lennie Chen, Asanda Gwashu-Nyangiwe, Hong Zhao, Ruwayhida Thebus, Nonkululeko Ndabambi, Sorachai Nitayaphan, Talita York, David Matten, Hugh Murrell, Alec Pankow, Michal Juraska, James Ludwig, John Hural, Myron Cohen, Lawrence Corey, M. Juliana McElrath, Peter Gilbert, Carolyn Williamson, Bruna Galvao, Fredrick Sawe
| Nature Verified
Abstract Understanding the selective forces acting upon HIV early in infection is crucial to design prevention strategies. By leveraging deep sequencing and the short diagnostic intervals of the FRESH and RV217 cohorts between the last-negative and first-positive RNA tests (median 4 days), we captured a precise and early snapshot of acute HIV infection.
Open in Who Shared Issue with article?

Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials

|
By Carolyn Williamson, Chivonne Moodley, Craig A Magaret, Elena Giorgi, Morgane Rolland, Dylan Westfall, Anna Yssel, Wenjie Deng, Nonhlanhla N. Mkhize, Lennie Chen, Hong Zhao, Tanmoy Bhattacharya, Alec Pankow, Ben Murrell, Ruwayhida Thebus, Paula Cohen Verified, Bronwen E. Lambson, Michal Juraska, Hongjun Bai, Allan C. deCamp, Maurine D Miner, James Ludwig, Yunda Huang, Lily Zhang, Daniel Reeves, Bryan Mayer, Shelly Karuna, John Hural, Lynn Morris, David C. Montefiori, Penny Moore, Paul T. Edlefsen, Srilatha Edupuganti, Nyaradzo Mgodi, M. Juliana McElrath, Myron Cohen, Lawrence Corey, Peter Gilbert, James Mullins, Raabya Rossenkhan, Talita York, Asanda Gwashu-Nyangiwe, Nonkululeko Ndabambi, Haajira Kaldine, Sinethemba Bhebhe, Cindy Molitor, Nicolas Beaume, David Matten, Roger E. Bumgarner
| Nature Verified
Abstract In the antibody mediated prevention (AMP) trials, the broadly neutralizing antibody (bNAb) VRC01 demonstrated protective efficacy against susceptible HIV strains. To understand how VRC01 shaped breakthrough infections, deep sequencing was performed on 172 participants (>100,000 gag-Δpol and rev-env-Δnef sequences), at diagnosis and over time, in the placebo and treatment arms of the African (HVTN703/HPTN081; NCT02568215) and Americas/Europe (HVTN704/HPTN085; NCT02716675) cohorts.
Open in Who Shared Issue with article?

Rare twin cysteine residues in the HIV-1 envelope variable region 1 link to neutralization escape and breadth development

|
By Maria C. Hesselman, Marius Zeeb, Peter Rusert, Chloé Pasin, Jennifer L. Mamrosh, Samuel Kariuki, Ian Pichler, Michèle E Sickmann, Masako M. Kaufmann, Daniel Schmidt, Nikolas Friedrich, Karin J. Metzner, Audrey Rindler, Herbert Kuster, Craig Adams, Ruwayhida Thebus, Michael Huber, Sabine Yerly, Karoline Leuzinger, Matthieu Perreau, Roger Koller, Günter Dollenmaier, Simona Frigerio, Dylan Westfall, Wenjie Deng, Allan C. deCamp, Michal Juraska, Srilatha Edupuganti, Nyaradzo Mgodi, Hugh Murrell, Nigel J. Garrett, Kshitij Wagh, James Mullins, Carolyn Williamson, Penny Moore, Huldrych F. Günthard, Roger Kouyos, Alexandra Trkola
| Cell Host & Microbe Verified
Keywords HIV vaccine envelope glycoprotein broadly neutralizing antibodies elite neutralizers V1V2 Env stabilization Introduction Genetic traits of the HIV-1 envelope glycoprotein (Env) that link to bnAb development and escape in untreated HIV-1 infection are key to vaccine immunogen development.
Open in Who Shared Issue with article?

Difference between revisions of "Image:Example rocks (1).jpg"

|
By Dylan Westfall
| wikiHow
Note: Only certain users can change "expertgreenbox" templates. If your edits affect that template, they won't be saved.
Open in Who Shared Issue with article?

Difference between revisions of "Image:Examplerock(1).jpg"

|
By Dylan Westfall
| wikiHow
Note: Only certain users can change "expertgreenbox" templates. If your edits affect that template, they won't be saved.
Open in Who Shared Issue with article?
Show More